Hikal Limited (IN:HIKAL)
:HIKAL
HIKAL Stock Chart & Stats
₹227.05
-₹7.35(-1.92%)
At close: 4:00 PM EST
₹227.05
-₹7.35(-1.92%)
Day’s Range― - ―
52-Week Range₹155.15 - ₹456.60
Previous CloseN/A
Volume141.84K
Average Volume (3M)34.88K
Market Cap
₹20.41B
Enterprise Value₹27.35B
Total Cash (Recent Filing)₹340.00M
Total Debt (Recent Filing)₹7.20B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jun 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)1.80
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio1.79
Price to Book (P/B)3.92
Price to Sales (P/S)2.66
P/FCF Ratio34.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2
Revenue Forecast (FY)₹16.63B
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Improving ProfitabilityA 55% gross margin indicates strong product-level pricing power and/or differentiated chemistry capabilities common in specialty chemicals. Sustained high gross margins provide a durable buffer against raw material inflation, support reinvestment into R&D/CDMO capacity, and underpin long-term margin resilience even if sales temporarily fluctuate.
Robust Cash Generation And Positive Free Cash FlowStrong OCF conversion and substantial TTM FCF demonstrate the business converts earnings into cash reliably. That cash profile supports capex for plant expansion, funds working capital during cycles, enables debt servicing, and gives management optionality for strategic investments or shareholder returns over the medium term.
Moderate Leverage And Stable Balance SheetA debt-to-equity around 0.6 and near-50% equity ratio indicate conservative-to-moderate leverage, preserving financial flexibility. Improved ROE signals better capital efficiency. Together these support capacity investments and provide a buffer against cyclical downturns without excessive refinancing risk.
Bears Say
Inconsistent Revenue GrowthErratic top-line performance undermines predictability of capacity utilization and long-term planning for CDMO contracts. Inconsistent revenue hampers scale benefits, makes margin and cash forecasts less reliable, and raises execution risk when funding plant expansions or long-cycle customer contracts.
Modest Net Margins Despite Strong Gross MarginsA large gap between high gross margins and modest net margins suggests elevated operating, R&D, or SG&A absorption. This limits the company's ability to translate product strength into bottom-line returns and makes profitability more sensitive to scale, pricing pressure, or cost inflation over the medium term.
Exposure To Cyclical End Markets And Order VariabilityDependence on pharma and agrochemical demand and on customer order timing creates structural volatility. Variability in volumes and product mix can swing utilization and margins, complicating long-term capacity planning and cash flow predictability, especially for multi-year CDMO/customer supply arrangements.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹155.15 and its highest was ₹456.60 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹20.41B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Jun 18, 2026 which is in 82 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Feb 11, 2026. The company reported ₹1.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.8.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.8 which represents an annual dividend yield of 0.58%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of ₹1.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.977%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides. The company collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and APIs. It also provides specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―
Unichem Laboratories Limited
―